Selection of the key articles and interviews published during the 2019 San Antonio Breast Cancer Symposium (SABCS)

The oncoXchange news team spent 4 hectic days in San Antonio, Texas publishing articles and recording interviews with a number of key opinion leaders who presented important new data during the symposium. Here is a selection of some of the most noteworthy news items.

New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1

Interview with: Ian E. Krop, MD, PhD

---

Polygenic Breast Cancer Risk Modification in carriers of High and intermediate Risk gene Mutations

Interview with Allison W. Kurian, MD, MSc

---

Activity of HER2 antibody-drug conjugate promising in breast cancer pretreated with T-DM1

Article by Wayne Kuznar for oncoXchange

---

KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC

Interview with Peter Schmid, MD, PhD

---

Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

Interview with Luca Gianni, MD

---

Ribociclib/letrozole has high biological activity in luminal B breast cancer (CORALLEEN trial from SOLTI research group)

Article by Wayne Kuznar for oncoXchange